Laboratory of Malaria Immunology and Vaccinology
Malaria causes over 200 million cases and 400,000 deaths annually, with African children and pregnant women at highest risk. Vaccines targeting Plasmodium's life cycle stages are crucial. LMIV, established in 2009, focuses on malaria vaccine development, combining basic research and product development to advance vaccine candidates, including the leading TBV candidate Pfs230D1, currently in phase 2 trials in Mali.
Reference News
Malaria causes over 200 million cases and 400,000 deaths annually, with African children and pregnant women at highest risk. Vaccines targeting Plasmodium's life cycle stages are crucial. LMIV, established in 2009, focuses on malaria vaccine development, combining basic research and product development to advance vaccine candidates, including the leading TBV candidate Pfs230D1, currently in phase 2 trials in Mali.